WISP1 Polymorphisms Contribute to Platinum-Based Chemotherapy Toxicity in Lung Cancer Patients

• Main Authors: Juan Chen, Jiye Yin, Xiangping Li, Ying Wang, Yi Zheng, Chenyue Qian, Ling Xiao, Ting Zou, Zhan Wang, Junyan Liu, Wei Zhang, Honghao Zhou, Zhaoqian Liu
• Format: Article
• Language: English
• Published: MDPI AG 2014-11-01
• Series: International Journal of Molecular Sciences
• Subjects: WISP1; lung cancer; genetic polymorphism; chemotherapy toxicity
• Online Access: http://www.mdpi.com/1422-0067/15/11/21011
• ISSN: 1422-0067

Platinum-based chemotherapy toxicity is always one of the serious problems from which lung cancer patients suffer. The genetic polymorphism of WISP1 was revealed to be associated with susceptibility and platinum-based chemotherapy response in our previous studies. In this study, we aimed to investigate the relationship of WISP1 genetic polymorphisms with platinum-based chemotherapy toxicity in lung cancer patients. A total of 412 lung cancer patients were enrolled in this study, and 28 polymorphisms of the WISP1 gene were genotyped by SequenomMassARRAY. We found that WISP1 polymorphisms (rs2929965, rs2929969, rs2929970, rs2929973 and rs754958) were related to the overall chemotherapy toxicity of lung cancer in subgroup analyses. Rs16904853, rs2929970, rs2977549 and rs2977551 (p = 0.021, 0.028, 0.024, 0.048, respectively) polymorphisms were significantly associated with hematologic toxicity. Rs2929946, rs2929970, rs2977519, rs2977536, rs3739262 and rs754958 (p = 0.031, 0.046, 0.029, 0.016, 0.042, 0.035, respectively) polymorphisms were significantly associated with the gastrointestinal toxicity of lung cancer. Genotypes of WISP1 may be novel and useful biomarkers for predicting platinum-based chemotherapy toxicity in lung cancer patients.